Literature DB >> 7399237

Beneficial effect of cholestyramine in sclerosing cholangitis.

D E Polter, V Gruhl, E H Eigenbrodt, B Combes.   

Abstract

Cholestyramine exerted a beneficial effect on the course of a patient with sclerosing cholangitis associated with ulcerative proctitis. Over a 6.5-yr period, discontinuation of cholestyramine resulted in episodes of RUQ pain and/or appearance of abnormalities in liver tests. Readministration of the resin was followed by disappearance of symptoms and normalization of test resuls. The mechanism of the beneficial effect of cholestyramine was not elucidated.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7399237

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


  8 in total

1.  Primary sclerosing cholangitis in India.

Authors:  S K Acharya; S Vashisht; R K Tandon
Journal:  Gastroenterol Jpn       Date:  1989-02

Review 2.  Animal models to study bile acid metabolism.

Authors:  Jianing Li; Paul A Dawson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-18       Impact factor: 5.187

3.  Alterations in microbiota and their metabolites are associated with beneficial effects of bile acid sequestrant on icteric primary biliary Cholangitis.

Authors:  Bo Li; Jun Zhang; Yong Chen; Qixia Wang; Li Yan; Rui Wang; Yiran Wei; Zhengrui You; Yikang Li; Qi Miao; Xiao Xiao; Min Lian; Weihua Chen; Dekai Qiu; Jingyuan Fang; M Eric Gershwin; Ruqi Tang; Xiong Ma
Journal:  Gut Microbes       Date:  2021 Jan-Dec

4.  Primary sclerosing cholangitis: a heterogenous disease.

Authors:  H H Thompson; H A Pitt; R K Tompkins; W P Longmire
Journal:  Ann Surg       Date:  1982-08       Impact factor: 12.969

Review 5.  Primary sclerosing cholangitis.

Authors:  Marina G Silveira; Keith D Lindor
Journal:  Can J Gastroenterol       Date:  2008-08       Impact factor: 3.522

Review 6.  Clinical features and management of primary sclerosing cholangitis.

Authors:  Marina-G Silveira; Keith-D Lindor
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

7.  Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial.

Authors:  D H Van Thiel; P Carroll; K Abu-Elmagd; H Rodriguez-Rilo; W Irish; J McMichael; T E Starzl
Journal:  Am J Gastroenterol       Date:  1995-03       Impact factor: 10.864

8.  Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids.

Authors:  Claudia Daniela Fuchs; Gustav Paumgartner; Veronika Mlitz; Victoria Kunczer; Emina Halilbasic; Nadja Leditznig; Annika Wahlström; Marcus Ståhlman; Andrea Thüringer; Karl Kashofer; Tatjana Stojakovic; Hanns-Ulrich Marschall; Michael Trauner
Journal:  Gut       Date:  2018-04-10       Impact factor: 23.059
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.